1Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem cell transplantation versus conventional chemotherapy as front-line therapy in high-risk,aggressive non-hodgkin's lymphoma: an Italian multicenter randomized trial.J Clin Oneol,2003,21:1255-1262.
2Magni M, Di Nicola M, Devizzi L, ctal. Successful in vivo purging of CD34- containing peripheral blood harvests in mantle and indent lymphoma:evidence for a role both chemotherapy and rituximab infusion.Blood ,2000,96:864-869.
3Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol,2003,30( suppl 2 ) :3-8.
4Press OW,Eary JF,Gooley T,et al. A phrase Ⅰ/Ⅱ trial of iodine-131-tositurnomab ( anti-CD20 ), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood,2000,96 : 2934-2942.
6Flohr T, Hess G, Kolbe K,et al. Rituxlmab in vivo purging is safety and effective in combination with CD34 positive selected autologous stem cell transplant for salvage therapy in B-NHL Bone Marrow Transplant,2002,29 : 769-775.
2Martelli M,Gheflinzoni F,De Renzo A,et al.Early autologous stem cell transplantation versus conventional chemotherapy as front-line therapy inhish-risk.aggressive non-hodgkin's lymphoma:an Italian multicenter randomized trial.J Clin Oncol,2003,21:1255-1262.
3Liu AY,Robinson RR,Murray ED,et al.Production of a mousehuman chimeric monoclonal antibody to CD20 with potent Fcdependent biologic activity.J Immunol,1987,139:3521-3526.
4LoBuglio AF,Wheeler RH,Trang J,et al.Mouse/human chimeric monoclonal antibody in man:Kinetics and immune response.Pro Natl Acad Sci USA,1989,86:4220-4224.
5Mueller BM,Romerdahl Ca,Gillies SD,et al.Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.J immunol,1990,144:1382-1386.
6Vose JM,Link BK,Grossbard ML,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma.J Clin Oncol,2001,19:389-397.
7Maloney DG,Smith B,Rose A.et al.Rituximab:mechanism of action and resistance.Semin Onod,2002,29:2-9.
8Ladetto M,Corradini P,Vallet S,et al.High rate of clinical and molecular remissions in follicular lymphoma patients receiving highdose sequential chemotherapy and autografting at diagnosis:a multicenter,prospective study by the Gruppo ltaliano Trapianto Midollo Osseo (GITMO).Blood,2002,100:1559-1565.
9Horwitz SM,Negrin RS,Blume KG,et al.Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.Blood,2004,103:777-783.
10Van Heeckeren WJ,Vollweiler J,Fu P,et al.Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma:in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device.Br J Haematol,2006,132:42-55.
